News
In celebration of Ophthalmology Times ' 50th anniversary, we asked leading experts in the field, in a perfect world, if they ...
2d
Stockhead on MSNHealth Check: Truscreen’s diagnosis is for revenue growth and cash flow break even
Cervical cancer diagnosis house Truscreen (ASX:TRU) says it should achieve cash flow break even by March next year.
A five-year-old boy from Kidderminster with a rare condition has received the "surprise of a lifetime" at his favourite football club.
This speculative ASX stock could be destined to almost double in value according to analysts at Bell Potter. Let's see ...
Patients with type 2 diabetes (T2D) on semaglutide or tirzepatide showed a higher incidence of nonarteritic anterior ischemic optic neuropathy and other optic nerve disorders compared to other ...
Attendance Allowance, a tax-free benefit administered by the Department for Work and Pensions ( DWP ), currently provides additional financial support to over 1.6 million people across Great Britain.
Stoke Therapeutics, Inc.'s zorevunersen shows promise in Dravet syndrome with FDA breakthrough designation. Click for my updated look at STOK stock.
8d
TipRanks on MSNPYC Therapeutics Advances PYC-001 for Blinding Eye Disease
An update from PYC Therapeutics Limited ( ($AU:PYC) ) is now available. PYC Therapeutics Limited announced the completion of dosing in its Phase 1 ...
Since the dawn of human spaceflight, scientists have carefully studied the effects of space and microgravity on astronauts.
Amylyx Pharmaceuticals has discontinued the clinical development program for AMX0035, for the treatment of progressive supranuclear palsy.
Avoiding and managing ocular radiotoxicity are increasingly important as more patients undergo radiotherapy for HNC, ...
Neurodegeneration in multiple sclerosis can be monitored via OCT of inner retinal layers in the macular region, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results